ADVOCATE. CONNECT. INNOVATE.

FOSUN BIOPHARMACEUTICAL PARTNERING AND CAREER FORUM

Palo Alto, CA

4/14/2018

2:0pm - 5:30pm

DESCRIPTION
Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Xuzhou Economic and Technological Development Zone will bring you this exciting networking opportunity with featured opportunities for collaboration, investment, and career development!

The event is organized by CABS

Title Sponsor:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, founded in 1994, is one of the leading biopharmas in China. Its business covers a wide range of key sectors in the healthcare value chain, including drug manufacture and R&D, medical service, medical device and diagnosis, pharmaceutical distribution, and retail. Fosun Pharma, equipped with a national enterprise technology center, has built a number of high-efficiency innovation platforms in the realm of chemical drug, biopharmaceutical medication, generics, and cellular immunity platform. At present, Fosun Pharma is holding the pole position in the development of several life science market segments in China, including the blood circulation system, central nervous system, metabolism and digestive system, anti-infection, cardiovascular, oncology, etc.

With the brand concept of “Innovation for Good Health”, Fosun Pharma is committed to becoming the world’s leading healthcare enterprise. In 2017 alone, Fosun Pharma’ revenue has reached a total of ¥18.5 billion, with ¥1.5 billion for R&D fund, and its market cap has exceeded ¥100 billion. Fosun, armed with a diversified and flexible investment cooperation model, is slated to pursue an international collaborative strategy in the coming years. In Jan of 2017, Fosun and Kite Pharma have penned a deal to co-develop and commercialize autologous T-Cell therapies for cancer treatment. And the red hot Yescarta is expected to bceom the first cell therapy product in China. Later of last year, Fosun Pharma has further acquired 74% of Gland Pharma with an over $1 billion investment.

The Bay Area promotional career forum hopes to have in-depth discussion with Fosun Pharma, led by Mr. Yifang Wu — the President and CEO, about its global cooperation and strategic blueprint. Experts, students, scholars, entrepreneurs, and investors with interests in medicine & healthcare are all welcome to attend.

Yifang Wu
Executive Director of Fosun Pharma
President of Fosun Pharma
Chief Executive Officer of Fosun Pharma

Mr. Yifang Wu, joined Fosun in April 2004, is the President and Chief Executive Officer of Fosun Pharma.

Prior to this, Mr. Wu has worked in the following positions.
– a Technician, Director, Production Officer, Finance Director, Assistant to Director of Xuzhou Biochemical Pharmaceutical Factory, now known as Wanbang Pharma, from June 1987 to April 1997
– The deputy Director of Xuzhou (Wanbang) Biopharmaceuticals Manufactures Plant, now known as Wanbang Pharma, from April 1997 to December 1998
– The president of Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd., now known as Wanbang Pharma and the Deputy General Manager of Wanbang Pharma from December 1998 to March 2007
– The president of Wanbang Pharma, from March 2007 to April 2011
– The chairman and CEO of Wanbang Pharma from April 2011 till now.

Xuzhou Economic and Technological Development Zone
Xuzhou Economic and Technological Development Zone, lies in an important strategic position of the “four vertical and four horizontal” system of the national railway network, is an important channel connecting the Beijing-Hangzhou Grand Canal Economic Belt and the Yangtze River Economic Belt. Founded in July 1992 and covering an area of 293.6 square kilometers, Xuzhou Economic and Technological Development Zone has upgraded to a state-level Economic and Technological Development Zone in March 2010. So far, there are 4125 enterprises including 13 Fortune 500 companies in the zone. Currently Xuzhou Economic and Technological Development Zone’s comprehensive strength ranks 7th provincially of all 137 Development Zones in Jiangsu and has become a zone with the largest scale, strongest strength, highest industry grade and of most investment value around the Huaihai Economic Region.

Career Forum Featured Participating Companies:
1) Biocytogen Inc. headquartered in Beijing is one of the global leaders in the gene targeted animal model production, preclinical in vivo efficacy studies, and pharmacological service.

Opening positions (United States):
- In vivo efficacy/Toxicity Director
- PK/PD Scientists
- PK/PD Research Associates
- BD Director or Manager

2)Applied StemCell Inc. (ASC) is a fast-growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production, and preclinical applications.

We are currently focusing on three areas: (1) cell line generation for bio-production and bioassays (2) patient-relevant cell models for personalized medicine and (3) physiologically predictive animal models of human diseases. We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.

Opening positions (United States):
- Scientist in Molecular Biology and Cell Genome Editing
- Scientist in R&D Department
- Scientist in Product Development Department
- Scientist, Therapeutic Development
- Research Associate (R&D Department)
- Research Associate
- Research Associate, Therapeutic development
- Research Associate, Genome Editing/ Engineering

3) Kelun Pharmaceutical
Founded in 1996, with over 100 subsidiaries globally; a public-traded company; one of the top 10 pharmaceutical companies in China with over 6 billion USD revenue in 2016

Kelun Pharmaceutical Research Institute
Over 1,300 R&D scientists; headquartered in Chengdu China with satellite research centers in Tianjin, Suzhou, and New Jersey; platforms include innovative small molecules and biologics, generic drugs, and new drug delivery systems; focusing on cancer, diabetes, liver, CNS, cardiovascular, and autoimmune diseases, etc; looking for in-licensing opportunities in biologics, cell therapy, oncolytic virus therapy, therapeutic nucleic acids, new drug delivery systems, small molecules for combination therapies.

Opening positions
- The Clinical Strategy Lead (CSL)
- Director, Early Stage Clinical Development
- Director, Late Stage Clinical Development
- Director, Clinical Operation Head
- Clinical Trials Liaison Officer (CTLO)
- Biologics Production Executive Director
- Director, Biologics Process Development
- Director of Biologics QA
- Director of Formulation Development
- Director of Generics Formulation(Solid Oral Products or Injectables)
More companies will be updated close to the event.

Event Schedule:
2:00 pm-2:30pm registration
Main Section:
2:30 pm – 2:40 pm Opening remarks: CABS, Dr. Cheni Kwok
2:40 pm – 3: 10 pm Keynote speech: Yifang Wu, President & CEO, Shanghai Fosun Pharmaceutical (Group) Co.,Ltd
3:10 pm – 3: 30 pm To be determined.
Career fair section:
3:30pm – 3:40 pm Biocytogen Inc.
3:40pm – 3:50 pm Applied StemCell Inc.
3:50pm – 4: 00 pm Kelun Pharmaceutical
Career fair and networking:
4:00 pm – 5: 30 pm

The schedule may be different on the day. The full job opening list and event details will be released one week before event.

Click Here for More Information

Contact: Jin Zhang
Contact Email: jin.zhang.ucla@gmail.com

Event Address:

120 Li Ka Shing Center for Learning and Knowledge (LKSC)
291 Campus Drive
Stanford, Palo Alto, CA 94305